![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Thursday, October 12, 2023 12:48:56 PM
Instead.
November 2021: The respected National Labor Secretary had seizures and was taken to a hospital where DCVax-l was likely not being utilized.
December 2021: Had Surgery and was diagnosed with GBM. The tumor was likely not frozen.
Next Margaret had radiation along with Merck’s chemotherapy Temodar (or possibly a generic).
Temodar left Margaret with an infection and her kidneys were not able to process the chemotherapy successfully. Temodar might end up killing her if continued.
Margaret had means to try something else privately, unfortunately she and her care team selected Bristol Myers’s Opdivo (now considered a mono therapeutic failure against GBM by their own company) and Genentech’s Avastin (never proven to extend survival, only temporarily gives false reading tumor is disappearing because it is anti angiogenic).
Her care providers also sent her to Germany for hyperthermia treatments, unfortunately the above therapies in those combinations likely do not allow her immune system to benefit from hyperthermia.
Her sister said there were no other treatments. Which is likely true, because if DCVax-l could not be used if tumor was not properly preserved or no longer met new definition of GBM, it was not an option — unfortunately.
In these types of cases, Dr. Mulholland is correct that it may take years to get an effective treatment, because, for instance, DCVax-Direct (which doesn’t need tumor preservation), and, thanks to you and other parasites, has lacked the funding to move into the next phase of trials.
June 2023: Margaret died 18 months after her diagnosis. (Probably 16 months after Chemotherapy began)
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM